Fibrillation data bode well for DU-176b as it moves to Phase III
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo's oral direct Factor Xa inhibitor DU-176b has moved into a pivotal Phase III study in atrial fibrillation (AF) patients after demonstrating safety comparable to warfarin at once-daily doses in a new Phase II trial.